Table 3.
Number of subsequent osteoporotic fractures and fracture by location
| FREEDOM analysis (3 years) | FREEDOM + Extension analysis (10 years) | ||
|---|---|---|---|
| Placebo N = 54 | Denosumab N = 24 | Combined Denosumab N = 144 | |
| Number of subsequent fractures, n (%) | |||
| 1 | 49 (90.7) | 22 (91.7) | 129 (89.6) |
| 2 | 4 (7.4) | 2 (8.3) | 14 (9.7) |
| 3 | 1 (1.9) | 0 (0) | 1 (0.7) |
| Subsequent fracture by location, n (%) | |||
| Spine | 39 (72.2) | 7 (29.2) | 70 (48.6) |
| Forearm | 4 (7.4) | 5 (20.8) | 29 (20.1) |
| Lower leg | 2 (3.7) | 1 (4.2) | 8 (5.6) |
| Hip | 1 (1.9) | 3 (12.5) | 8 (5.6) |
| Thorax | 3 (5.6) | 1 (4.2) | 7 (4.9) |
| Shoulder | 2 (3.7) | 3 (12.5) | 7 (4.9) |
| Foot | 1 (1.9) | 2 (8.3) | 5 (3.5) |
| Thigh | 0 (0) | 1 (4.2) | 5 (3.5) |
| Pelvis | 1 (1.9) | 1 (4.2) | 4 (2.8) |
| Hand | 1 (1.9) | 0 (0) | 1 (0.7) |
N number of subjects who had at least one subsequent osteoporotic fracture, n number of subjects